Leukos Biotech is a biopharmaceutical company focused on the development of new treatments for Acute Myeloid Leukaemia and other haematological malignancies. The company was founded in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute (IJC) and has a strong scientific, institutional and economic support from the IJC and the Josep Carreras Leukaemia Foundation, among other partners and collaborators. The company has closed a licensing agreement with the Austrian pharmaceutical company AOP-Health to develop LB208, the first clinical candidate, in oncological indications starting with haematological tumors. Leukos, together with VHIR and Leitat, received in November 2022 a 1,4M€ grant/loan (CPP2021-008715) investigate further the mechanism of action of LB208, a tumor-specific oral HTR1B antagonist, and to perform an exploratory clinical trial
Company Details
- Employees
- 5
- Founded
- 2015
- Address
- Muntaner 383, 3º 2ª, Barcelona,spain
- Phone
- 34931998148
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- leukosbiotech.com
- Keywords
- leukemia, hematology, AML.
- HQ
- Barcelona
Leukos Biotech Questions
Leukos Biotech's helpline number is 34931998148
Leukos Biotech's website is leukosbiotech.com
Leukos Biotech's LinkedIn profile is https://es.linkedin.com/company/leukos-biotech
Leukos Biotech has
5 employees.
View email and phone details for 5
employees at Leukos Biotech.
Leukos Biotech's industry is
Pharmaceutical Manufacturing
Leukos Biotech's top competitors are
Oniria Therapeutics,
Aelix Therapeutics,
Der Standard,
Parc Científic De Barcelona,
Josep Carreras Leukaemia Research Institute (Ijc),
Innosens,
Quatre Lab,
Caixaresearch Institute,
Aop Health,
Reig Jofre.
Leukos Biotech's categories are Pharmaceutical Manufacturing
Leukos Biotech's founding year is 2015
